Pain News and Research

Latest Pain News and Research

Creabilis initiates CT327 Phase IIb trial in psoriasis vulgaris

Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, today announced the start of the Phase IIb global clinical trial of its lead product CT327 in patients with psoriasis vulgaris. Recruitment is progressing well.

29 Feb 2012

Minimally invasive treatments to be showcased at SIR's 37th Annual Scientific Meeting

The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries that may change the way dozens of diseases are treated at its 37th Annual Scientific Meeting March 24-29 at San Francisco's Moscone Center.

29 Feb 2012

Wiley-Blackwell to publish 44 new important journals in 2012

In 2012 Wiley-Blackwell, the Scientific, Technical, Medical, and Scholarly publishing business of John Wiley & Sons, Inc., will begin publishing 44 titles new to its journal program, including 16 new launches and 40 journals published in collaboration with societies or other organizations.

29 Feb 2012

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2011, and provided an update on the Company's key business initiatives.

29 Feb 2012

Cannabinoids may be a target for new strategies in cancer treatment

Cannabis-like substances that are produced by the body have both therapeutic and harmful properties, besides their well-known intoxicating effects, and the body's cannabinoid system may be a target for new strategies in cancer treatment.

29 Feb 2012

Minn. Senate takes on anti-abortion bills; Texas to cut women's health programs; 'Personhood' initiatives advance

Across the nation, state legislatures are considering various bills to restrict access to abortion and contraception services.

29 Feb 2012

Obesity can decrease risk of mortality in people over 85 years of age

Obesity is considered the leading preventable cause of death worldwide - until you reach old age, that is. Though obesity increases the risk of an early death, shaving an average of six to seven years off a person's lifespan, Tel Aviv University researchers have found that this trend may reverse itself after the age of 85. In these people, excess fat seems to have a "protective" effect, decreasing the risk of death when compared to those who are considered at a normal body weight.

29 Feb 2012

TUT creates first biodegradable joint implant for arthritic patients

Tampere University of Technology (TUT), Finland, has been the first in the world to develop biodegradable joint implant, RegJoint-. The implant is used in the treatment of osteoarthritis and rheumatoid arthritis.

29 Feb 2012

Silver Hill Hospital announces opening of Chronic Pain and Addiction Center

Silver Hill Hospital, the nationally recognized psychiatric hospital in New Canaan, CT, announces the opening of the Chronic Pain and Addiction Center, an intensive residential treatment program for patients with pain who have become addicted to opioid medications.

28 Feb 2012

Biogen Idec receives FDA approval for two separate dosing innovations to treat MS

Today Biogen Idec announced that the U.S. Food and Drug Administration (FDA) has approved two separate dosing innovations designed to improve the treatment experience for patients receiving once-a-week AVONEX for relapsing forms of multiple sclerosis (MS).

28 Feb 2012

Baxter commences CD34+ stem cell phase III trial in CMI

Baxter International Inc. announced today that it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (an individual's own) CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia (CMI).

From Baxter International Inc. 28 Feb 2012

HPV vaccine now recommended for boys: American Academy of Pediatrics

Pediatricians in the U.S. say it's now time for boys, as well as girls, to be vaccinated against human papillomavirus or HPV. The American Academy of Pediatrics has updated its guidance to parents and doctors in favor of routine immunization for boys against the virus. Earlier the AAP had said it was OK to vaccinate boys against the HPV, but it only became part of the pediatricians' official schedule of recommended vaccines this month.

28 Feb 2012

Stents not more beneficial than medications in stable coronary artery disease: Study

The placement of a stent to repair a narrowed artery in the heart has become routine worldwide. A new analysis of earlier clinical trials shows that inserting a stent has no benefit over standard medical care in treating stable coronary artery disease.

28 Feb 2012

Gedeon Richter and Forest Labs' cariprazine Phase III trials on schizophrenia meet primary endpoint

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for the treatment of acute exacerbation of schizophrenia.

28 Feb 2012

New approaches may increase effectiveness of SCS for severe back pain

New approaches to electrical stimulation—using an implanted device with three columns of electrodes—may increase the effectiveness of spinal cord stimulation (SCS) for severe back pain, suggests a study in the March issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

28 Feb 2012

Older women with recurrent pain more likely to develop depression, obesity

Women age 50 and older who experience worsening pain with aging also have a higher risk for depression, obesity and declining physical function, according to research reported in The Journal of Pain, the peer-review publication of the American Pain Society.

28 Feb 2012

FDA assigns Priority Review designation to JRD's XARELTO sNDA

Janssen Research & Development, LLC (JRD) announced today that the U.S. Food and Drug Administration (FDA) has assigned a Priority Review designation to the supplemental New Drug Application (sNDA) filed on December 29, 2011 for XARELTO (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS).

27 Feb 2012

St. Jude Medical quarterly dvidend increases to $0.92 per share

St. Jude Medical, Inc., a global medical device company, today announced that its Board of Directors declared a 10 percent increase in the company's quarterly dividend to $0.23 per common share. At the new rate, the annual dividend would be $0.92 per share, compared to the previous annual dividend of $0.84 per share.

27 Feb 2012

GE Healthcare Discovery MR750w 3.0T scanner installed at BRMI

Patients and clinicians alike are celebrating the newest arrival at BRMI@ Dyker Heights of an innovative GE Healthcare Discovery MR750w 3.0T scanner.

27 Feb 2012

ATI commences European trial of neurostimulation system for migraine

Autonomic Technologies, Inc. (ATI), the developer of a novel miniaturized implantable stimulator for severe headaches, today announced initiation of a study in Europe to evaluate the safety and efficacy of the company's investigational neurostimulation system for the treatment of high frequency, high disability migraine.

27 Feb 2012